Peptide Library

Human study PLS-00209

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Other design · 72 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Study of Thymosin Beta 4 in Patients With Pressure Ulcersregistry entry · NCT00382174 (COMPLETED, results posted, planned enrollment 72)

Design and participants

Design
Other design
Population
Patients with pressure ulcers
Conditions
Pressure Ulcers
Planned enrollment (registry)
72
Enrolled
72
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Thymosin Beta 4 (intervention) · thymosin-beta-4 · Thymosin beta 4, as listed among the registry interventions · Not reported assigned
  • Placebo (comparator) · Placebo, as listed among the registry interventions · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • other: Only the registry entry is available. No publication, abstract or posted outcome data are included in the record, so effects cannot be appraised.
  • inadequate randomization: The record lists placebo and thymosin beta 4 interventions but does not state that participants were randomized or how allocation was done.
  • inadequate blinding: The registry fields in the record give no information on masking of participants, caregivers or outcome assessors.
  • selective reporting: No outcomes are named in the record, so the reported results cannot be checked against prespecified endpoints.
  • small or imprecise: Actual enrollment was 72 participants across both groups, which is modest for a phase 2 wound-healing study.
  • abstract only: No publication or abstract is available; randomization and blinding are not described, only a placebo intervention is listed.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT00382174, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT00382174, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT00382174, registry (has_results and interventions fields) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT00382174, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT00382174, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).